J Refract Surg. 2023 Aug;39(8):524-530. doi: 10.3928/1081597X-20230424-01. Epub 2023 Aug 1.
To compare the visual outcomes of bilateral implantation of two commercially available trifocal intraocular lenses (IOLs) (AcrySof IQ PanOptix IOL; Alcon Laboratories, Inc and AcrivaUD Trinova IOL; VSY Biotechnology).
This comparative, investigator-initiated, single-center randomized trial was conducted by the Department of Ophthalmology of the Medipol Mega University Hospital in Istanbul, Turkey. Adult patients were randomized in a 1:1 ratio using a block randomization program to undergo cataract surgery and receive the implantation of either the PanOptix or Trinova IOL in both eyes. Outcome measures including binocular uncorrected and corrected visual acuities at distance, intermediate (66 cm), and near (40 cm), defocus curve, refractive outcomes, contrast sensitivity, glare and halos, and patient satisfaction were assessed at a minimum of 3 months following bilateral IOL implantation.
A total of 71 patients (142 eyes) were included, with 35 patients (70 eyes) in the PanOptix IOL group and 36 patients (72 eyes) in the Trinova IOL group. At the 3-month follow-up examination, mean distance-corrected intermediate visual acuity (primary endpoint) was significantly better for the PanOptix IOL group (0.0 ± 0.09 logMAR) compared with the Trinova IOL group (0.01 ± 0.10 logMAR) ( = .0304). Mean logMAR uncorrected intermediate acuity (UIVA) and near (UNVA) visual acuity were also significantly better for the PanOptix IOL group (UIVA = 0.1 ± 0.10 logMAR; UNVA= 0.0 ± 0.09 logMAR) compared with the Trinova IOL group (UIVA = 0.2 ± 0.10 logMAR; UNVA = 0.2 ± 0.11 logMAR) (both < .001). There were no statistically significant differences in all other outcomes between groups. No adverse events were reported in both groups.
These results suggest that the PanOptix IOL provides better intermediate and near visual outcomes compared to the Trinova IOL and represents a good choice for patients seeking to achieve spectacle independence. .
比较两种市售三焦点人工晶状体（IOL）（AcriSof IQ PanOptix IOL；Alcon Laboratories，Inc.和 AcrivaUD Trinova IOL；VSY Biotechnology）双侧植入的视觉效果。
这项由土耳其伊斯坦布尔 Medipol Mega 大学医院眼科进行的比较、研究者发起的、单中心随机试验，采用区组随机化程序将成年患者按 1:1 比例随机分为两组，分别接受 PanOptix 或 Trinova IOL 双眼植入。术后 3 个月以上，对双眼未矫正和矫正的远、中（66cm）和近（40cm）视力、离焦曲线、屈光结果、对比敏感度、眩光和光晕以及患者满意度等结果进行评估。
共纳入 71 例（142 只眼）患者，其中 PanOptix IOL 组 35 例（70 只眼），Trinova IOL 组 36 例（72 只眼）。在术后 3 个月的随访检查中，PanOptix IOL 组的平均远距矫正中间视力（主要终点）显著优于 Trinova IOL 组（0.0±0.09 logMAR）（=0.0304）。PanOptix IOL 组的平均 logMAR 未矫正中间视力（UIVA）和近视力（UNVA）也显著优于 Trinova IOL 组（UIVA=0.1±0.10 logMAR；UNVA=0.0±0.09 logMAR）（均<0.001）。两组间其他结果均无统计学差异。两组均未报告不良事件。
这些结果表明，与 Trinova IOL 相比，PanOptix IOL 提供了更好的中距和近距视力结果，是寻求实现脱镜目标的患者的良好选择。
